TRAZEN-MF Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
TRAZEN-MF
Tranexamic Acid 500mg + Mefenamic Acid 250mg
TRAZEN-MF (Tranexamic Acid 500mg + Mefenamic Acid 250mg) is manufactured under strict WHO-GMP compliance for maximum bioavailability and therapeutic efficacy.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
The active pharmacological principles in TRAZEN-MF deliver targeted therapeutic action through standardized systemic bioavailability and verified pharmacodynamics.
As directed by the registered medical practitioner. Strictly adhere to full course duration.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
TRAZEN-MF features Tranexamic Acid 500mg + Mefenamic Acid 250mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
High therapeutic compliance and optimal bio-absorption
Prescribed TRAZEN-MF extensively in our OPD practice. Excellent bioavailability, quick absorption, and well-tolerated across diverse patient demographics. The quality of active pharmaceutical ingredients (API) is visibly superior compared to market alternatives.
Questions Regarding TRAZEN-MF
What is the therapeutic indication and composition of TRAZEN-MF?
TRAZEN-MF contains Tranexamic Acid 500mg + Mefenamic Acid 250mg indicated for Indicated for therapeutic management within specified clinical indications under qualified physician guidance. as formulated by Sygnus Biotech.
What packaging presentations are available for TRAZEN-MF?
TRAZEN-MF is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for TRAZEN-MF?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for TRAZEN-MF along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
TRAZEN-MF is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
